AGPS and rheumatoid arthritis: In biomarker analysis of two phase III trials (MOBILITY involving RA patients with inadequate response to prior methotrexate and TARGET involving RA patients with inadequate response to prior TNF inhibitors), ADAs response rates were 5.6% (150 sarilumab) and 4.0% (200 mg sarilumab) and neutralizing antibodies were detected at 1.6% and 1.0% (346).